Clinical Trials
16 trialsNCT04729387 2026-06-04
Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected
Novartis
Phase 3 Terminated
NCT02446600 2026-06-03
Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT07564141 2026-06-03
RAINFOLâ„¢-07
Genmab
Phase 3 Not yet recruiting
NCT05564377 2026-06-02
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05739981 2026-06-02
MRD
Imunon
Phase 1/2 Recruiting
NCT06619236 2026-06-02
RAINFOL-02
Genmab
Phase 3 Active not recruiting
NCT06915025 2026-06-02
OVATION-3
Imunon
Phase 3 Recruiting
NCT07604766 2026-06-02
RAINFOL-02
Genmab
Phase 3 Not yet recruiting
NCT05039801 2026-06-01
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT07214779 2026-06-01
MAESTRA 2
Incyte Corporation
Phase 3 Recruiting
NCT01081262 2026-05-29
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT05185947 2026-05-29
Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT07213804 2026-05-27
FRAmework-01
Eli Lilly and Company
Phase 3 Recruiting
NCT07286266 2026-05-27
A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
GlaxoSmithKline
Phase 3 Not yet recruiting
NCT06161025 2026-05-22
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Daiichi Sankyo
Phase 2/3 Recruiting
NCT07042802 2026-05-18
A Phase Ib/â…¡ Clinical Trial of LBL-024 Combined With Paclitaxel in Patients With Platinum-resistant Ovarian Cancer
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2 Recruiting